Christopher Durant Turner - 05 Jan 2024 Form 4 Insider Report for Nuvalent, Inc. (NUVL)

Role
Chief Medical Officer
Signature
/s/ Deborah Ann Miller, attorney-in-fact
Issuer symbol
NUVL
Transactions as of
05 Jan 2024
Transactions value $
$0
Form type
4
Filing time
09 Jan 2024, 16:55:55 UTC
Previous filing
06 Oct 2023
Next filing
08 Jan 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NUVL Class A Common Stock Award $0 +33.3K +229.45% $0.00 47.8K 05 Jan 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NUVL Stock Option (Right to Buy) Award $0 +47.5K $0.00 47.5K 05 Jan 2024 Class A Common Stock 47.5K $72.35 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Consists of shares of Nuvalent, Inc. Class A Common Stock issuable under restricted stock units ("RSUs"). Each RSU represents the right to receive one share of Nuvalent, Inc. Class A Common Stock. The RSUs vest in three equal annual installments following January 5, 2024, subject to continued service to Nuvalent, Inc. through the applicable vesting date.
F2 The shares underlying this option vest over the next four years in equal monthly installments following January 5, 2024, subject to continued service to Nuvalent, Inc. through the applicable vesting date.